NASD · Healthcare · Biotechnology · USA
Celcuity Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Celcuity is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a kinase inhibitor that comprehensively blocks the PI3K/AKT/mTOR signaling pathway across multiple isoforms and complexes. The company is evaluating gedatolisib in clinical trials for hormone receptor-positive, HER2-negative advanced breast cancer and castration-resistant prostate cancer.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Celcuity Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on CELC yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.